Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026)

Trevi Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$190000.0 for Q1 2026.

• In Q1 2026, Retained Earnings rose 99.94% year-over-year to -$190000.0; the TTM figure through Mar 2026 stood at -$190000.0 (up 99.94% YoY), while the FY2025 annual figure was $512.8 million, up 840509.84% from the prior year.
• Retained Earnings for Q1 2026 stood at -$190000.0, down from $512.8 million in the prior quarter.
• The five-year high for Retained Earnings was $512.8 million in Q4 2025, with the low at -$321.5 million in Q3 2025.
• The 5-year median for Retained Earnings is -$135000.0 (2022), against an average of -$7.0 million.
• Peak annual rise in Retained Earnings reached 840509.84% in 2025, while the deepest fall reached 368573.81% in 2025.
• Trevi Therapeutics' Retained Earnings stood at -$122000.0 in 2022, then sank by 195911.48% to -$239.1 million in 2023, then soared by 100.03% to $61000.0 in 2024, then surged by 840509.84% to $512.8 million in 2025, then plunged by 100.04% to -$190000.0 in 2026.
• Business Quant data shows TRVI's Retained Earnings at -$190000.0 in Q1 2026, $512.8 million in Q4 2025, and -$321.5 million in Q3 2025.